Intrinsiqq
bioMérieux SA logo

bioMérieux SA Quality Score

BIM.XPAR

⊜ Compare
Quality65

Growth remains strong (avg 75/100), but valuation is pulling the composite down (avg 60/100).

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
60/100
29.0x

25–30x, paying a growth premium

Cash Flow Multiple
60/100
25.4x

25–30x, paying up for cash generation

Revenue Growth
50/100
4.3%

2–5% CAGR, growing but slowly

Cash Flow Growth
100/100
34.0%

Above 10% CAGR, strong compounder

Business Quality & Capital Allocation

Share Dilution
80/100
-0.2%

Roughly flat, no meaningful dilution

Margin Trend
20/100
-0.4pp

Modest contraction, within normal range

Capital Structure
100/100
-€108M

Net cash position, no leverage concern

2022
€553M
€505M
2023
€352M
€519M
2024
€450M
€490M
2025
€570M
€461M
CashDebt
Return on Capital
60/100
11.3%

10–15%, respectable returns

Customize WeightsPremiumUpgrade

bioMérieux SA (BIM.XPAR) quality: score, margins and returns

bioMérieux SA (BIM.XPAR) scores 65/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 8 metrics each scored 0 to 100, on 17.1% operating margins and 11.3% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.

Frequently asked

Is bioMérieux SA (BIM.XPAR) a high-quality business?+

bioMérieux SA scores 65 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a 17.1% operating margin and a 11.3% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does bioMérieux SA's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BIM.XPAR's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where bioMérieux SA scores well and where it falls behind.

What is bioMérieux SA's return on invested capital (ROIC)?+

bioMérieux SA earns about 11.3% on its invested capital, which is solid. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to BIM.XPAR's margins and growth on this scorecard to judge durability.

How profitable is bioMérieux SA?+

bioMérieux SA runs an operating margin of about 17.1% and a net margin of about 9.8%. Revenue has grown at roughly 4.8% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from company filings, not investment advice.

How the market compares: US profitability statistics

Peers

Diagnostics & Research · Pick stocks to compare with BIM.XPAR

CompareIntrinsic value
IPN.XPARIpsen
€155.80+1.70%60
ORP.XPAROrpea
€10.20+2.93%26
GDS.XPARRamsay Générale de Santé SA
€8.62-1.37%49
CLARI.XPARClariane SE
€3.31+3.43%45
EMEIS.XPAREmeis SA
€10.20+2.93%56
LNA.XPARLNA Santé SA
€25.50+4.51%46
EAPI.XPAREuroapi S.A.S.U.
€0.82+2.11%46
GBT.XPARGuerbet SA
€6.26-0.95%38

Held by ETFs

BIM.XPAR is in 49 US ETFs. The largest of them, with BIM.XPAR's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BIM.XPAR

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.